logo BDSP

Base documentaire


  1. The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women.

    Article - En anglais

    Purpose and Methods

    We used decision analysis to model the natural history of breast cancer in hypothetical cohorts of 45-year-old women receiving tamoxifen, chemotherapy, or combined therapy.

    We used recurrence and efficacy data from the Early Breast Cancer Triallsts' Collaborative Group (EBCTCG), utility values from focus groups, and costs from clinic charges and Medicare data.

    Results

    Tamaxifen alone provides minimal benefit in estrogen receptor-negative (ER-; 0.2 to 0.4 months) and modest benefit in receptor-positive (ER+; 3.5 to 5.2 months) cancer.

    Chemotherapy adds substantial benefit independent of receptor status.

    (4.9 to 1 0.7 quality-adjusted months).

    Mots-clés Pascal : Tumeur maligne, Tamoxifène, Analyse coût efficacité, Glande mammaire, Efficacité traitement, Glande mammaire pathologie, Antioestrogène, Anticancéreux, Préménopause, Economie santé, Chimiothérapie, Traitement adjuvant, Adulte, Homme

    Mots-clés Pascal anglais : Malignant tumor, Tamoxifene, Cost efficiency analysis, Mammary gland, Treatment efficiency, Mammary gland diseases, Antiestrogen, Antineoplastic agent, Premenopause, Health economy, Chemotherapy, Adjuvant treatment, Adult, Human

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 93-0464518

    Code Inist : 002B02R02. Création : 199406.